Cortés, J., Hochhaus, A., Flynn, K., Bombaci, F., Issa, G., Larson, R., Wang, J., Kim, D., Kim, D., Mayer, J., Goh, Y. T., Coutre, P. L., Kim, I., Etienne, G., Kapoor, S., Jinwal, R., Malek, K., Yau, L., Hughes, T., Takahashi, N. (2025). Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis. Blood. https://doi.org/10.1182/blood-2025-1997